See more : Canada Carbon Inc. (CCB.V) Income Statement Analysis – Financial Results
Complete financial analysis of Cannara Biotech Inc. (LOVFF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cannara Biotech Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Scientia School, S.A. (MLSCI.PA) Income Statement Analysis – Financial Results
- Gun Ei Chemical Industry Co., Ltd. (4229.T) Income Statement Analysis – Financial Results
- Swadeshi Polytex Limited (SWADPOL.BO) Income Statement Analysis – Financial Results
- Al Moammar Information Systems Company (7200.SR) Income Statement Analysis – Financial Results
- TotalEnergies SE (FP.SW) Income Statement Analysis – Financial Results
Cannara Biotech Inc. (LOVFF)
About Cannara Biotech Inc.
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivated products in Canada. It also offers hemp-based CBD products through e-commerce platform. The company was incorporated in 2017 and is headquartered in Saint-Laurent, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | 81.75M | 57.26M | 35.84M | 17.02M | 2.55M | 2.10M | 432.64K |
| Cost of Revenue | 51.96M | 30.03M | 18.51M | 6.72M | 1.33M | 403.90K | 273.58K |
| Gross Profit | 29.79M | 27.23M | 17.33M | 10.30M | 1.22M | 1.69M | 159.06K |
| Gross Profit Ratio | 36.44% | 47.56% | 48.36% | 60.50% | 48.00% | 80.74% | 36.76% |
| Research & Development | 1.12M | 1.03M | 1.26M | 1.91M | 2.60M | 0.00 | 0.00 |
| General & Administrative | 12.97M | 10.61M | 8.59M | 6.16M | 8.06M | 10.58M | 1.60M |
| Selling & Marketing | 6.68M | 2.91M | 1.44M | 1.14M | 904.66K | 765.93K | 271.35K |
| SG&A | 19.65M | 13.52M | 10.03M | 7.30M | 8.97M | 11.35M | 1.87M |
| Other Expenses | -1.06M | 792.03K | 0.00 | 24.44K | 25.89K | 0.00 | 0.00 |
| Operating Expenses | 19.71M | 15.34M | 12.36M | 10.00M | 13.15M | 11.92M | 1.98M |
| Cost & Expenses | 71.67M | 45.37M | 30.87M | 16.72M | 14.48M | 12.32M | 2.25M |
| Interest Income | 178.96K | 0.00 | 92.69K | 52.79K | 265.77K | 679.62K | 27.09K |
| Interest Expense | 4.33M | 4.29M | 1.92M | 1.57M | 1.33M | 1.51M | 319.93K |
| Depreciation & Amortization | 6.35M | 4.94M | 3.92M | 3.03M | 2.58M | 566.33K | 109.68K |
| EBITDA | 15.16M | 15.77M | 8.40M | 3.06M | -9.19M | -10.89M | -1.68M |
| EBITDA Ratio | 18.55% | 27.54% | 21.18% | 18.91% | -357.47% | -428.81% | -389.08% |
| Operating Income | 10.08M | 11.89M | 4.94M | 257.28K | -11.95M | -10.22M | -1.82M |
| Operating Income Ratio | 12.33% | 20.76% | 13.78% | 1.51% | -468.56% | -487.52% | -420.01% |
| Total Other Income/Expenses | -5.59M | -4.94M | -2.64M | -1.79M | -1.14M | -2.75M | -295.77K |
| Income Before Tax | 4.48M | 6.95M | 2.31M | -1.53M | -13.09M | -12.97M | -2.11M |
| Income Before Tax Ratio | 5.49% | 12.13% | 6.43% | -8.98% | -513.33% | -618.60% | -488.38% |
| Income Tax Expense | -1.95M | 0.00 | 1.92M | 1.57M | 713.90K | 855.93K | 24.17K |
| Net Income | 6.44M | 6.95M | 2.31M | -1.53M | -12.48M | -12.32M | -2.11M |
| Net Income Ratio | 7.88% | 12.13% | 6.43% | -8.98% | -489.35% | -587.28% | -488.38% |
| EPS | 0.00 | 0.08 | 0.03 | -0.02 | -0.17 | -0.17 | -0.03 |
| EPS Diluted | 0.00 | 0.08 | 0.03 | -0.02 | -0.17 | -0.17 | -0.03 |
| Weighted Avg Shares Out | 0.00 | 89.30M | 87.67M | 76.52M | 71.33M | 70.68M | 69.38M |
| Weighted Avg Shares Out (Dil) | 0.00 | 89.30M | 87.84M | 76.52M | 71.33M | 70.68M | 69.38M |
Cannara Biotech Inc. Reports Record Q3 2023 Financial Results with Net Revenues of $15.9 Million and Net Income of $2.9 million
Three- and nine-month net revenue were $15.9 million and $39.3 million, a 57% and 63% increase compared to the same periods of prior year Delivered its ninth consecutive quarter of positive Adjusted EBITDA of $3.9 million, a 129% increase compared to Q3...
Cannara Biotech Inc. to Host Investor Webcast on August 17th, 2022
MONTREAL , Aug. 10, 2022 /PRNewswire/ - Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with one of the largest indoor cannabis cultivation facilities in...
Cannara Biotech Shares Surge On 983% QoQ Revenue Growth, Positive Adjusted EBITDA
Vertically integrated cannabis company Cannara Biotech Inc. (TSXV:LOVE) (OTCQB:LOVFF) (FRA: 8CB) released its fourth quarter and fiscal year 2021 financial and operating results on Wednesday with quarterly revenue of CA$6.5 million ($5.12 million), up by 983.33% from CA$600,000 in the same period a...
Cannara Biotech Cannabis Co. Slightly Beats Estimates, Posts $7.2M In Q3 2021 Revenue
Vertically integrated cannabis company Cannara Biotech Inc. (TSXV:LOVE) (OTCQB:LOVFF) (FRA: 8CB) reported Wednesday that it had generated $7.2 million in the third quarter of 2021, slightly beating previous estimates. The sum, which represents a year-over-year increase of 837%, includes $5.9...
Cannabis Industry Investor Presentations Now Available for On-Demand Viewing
NEW YORK, July 1, 2021 /PRNewswire/ -- Virtual Investor Conferences® and KCSA Strategic Communications today announced that the presentations from the June 29 th & 30th Cannabis Industry Virtual lnvestor Conference are now available for on-demand viewing at VirtualInvestorConferences.com. REGISTER OR...
Cannara Biotech Cannabis Co. Expects To Post $7.1M In Q3 Revenue After Successful Market Launch In Quebec
Cannara Biotech Inc. (TSXV:LOVE) (OTCQB:LOVFF) (FRA: 8CB) disclosed Monday it expects to generate roughly $7.1 million in the third quarter of 2021. That's a $5.1 million revenue growth compared to the prior period.
Cannara Biotech to Webcast Live at VirtualInvestorConferences.com June 30th at 11:30 ET
MONTREAL, June 25, 2021 /PRNewswire/ -- Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB) is a vertically integrated producer of premium–grade cannabis products for the Quebec and Canadian markets, today announced that Nicholas Sosiak, Chief Financial Officer...
Cannabis Co. Green Organic Dutchman Completes Sale Of Quebec Facility To Cannara Biotech
Cannabis producer The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (OTCQX:TGODF) has sold its Valleyfield, Quebec-based facility to Cannara Biotech Inc. (TSXV:LOVE) for $32.7 million.
/C O R R E C T I O N -- Cannara Biotech Inc./
In the news release, Cannara Biotech Enters Into Agreement to Acquire TGOD's State-of-the-art Cultivation and Manufacturing Facility in Valleyfield, Quebec, issued 10-Jun-2021 by Cannara Biotech Inc. over CNW, please note that the wrong version of the press release was sent...
Cannara Biotech Enters Into Agreement to Acquire TGOD's State-of-the-art Cultivation and Manufacturing Facility in Valleyfield, Quebec
Newly built fully automated one million sq. ft. facility increases Company's capacity of premium-grade cannabis up to 125,000 kg annually MONTREAL, June 10, 2021 /PRNewswire/ - Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a...
Source: https://incomestatements.info
Category: Stock Reports